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ihe controversies, successes, and unanswered questions that
ypify the unique, ongoing narrative history of dyslipidemia
s a coronary risk factor have had profound effects on policy,
atient care, and basic science (1,2). Although this lecture
ill draw from multiple sources, including my own personal
xperience, a brief synthesis of the state of the art such as
his cannot possibly capture the contributions of all of the
any investigators over the decades whose laboratories have
elineated the diverse threads that intertwine dyslipidemia,
therosclerosis, and cardiovascular disease. Nevertheless, I
ill attempt to examine some of the most current and
mportant topics as well as give my own personal perspective
f how this field has evolved since I first came to it in 1967
t the National Institutes of Health (NIH), in the laboratory
f Donald Fredrickson and Robert Levy.
HAT IS THE LIPID HYPOTHESIS?
ased on a substantial body of observational, pathological,
nd clinical data, the lipid hypothesis holds that reducing
igh levels of cholesterol, particularly low-density lipopro-
ein cholesterol (LDL-C), decreases the risks for developing
therosclerosis. The pathologist Felix Marchand first pro-
osed the term “atherosclerosis” in 1904, from the Greek
athero,” meaning gruel or porridge, and “sclerosis,” mean-
ng hardening, to describe the fatty mush that he observed
nside a hardened artery (3). Atherosclerosis begins as a
isease primarily of the intima. The two main components
elieved to be involved in the atherosclerosis, or athero-
hrombosis, process were described in the mid-19th century
y Karl von Rokitansky, who thought that atherosclerosis
egan with deposition in the intima of small blood clots
ith subsequent organization by the infiltration of fibro-
lasts and secondary lipid deposition, and by Rudolf Vir-
how, the German pathologist, who proposed that lipid
nsudation, vascular intimal injury, and inflammation in the
rterial wall were the major mechanisms of plaque develop-
ent (4).
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Manuscript received June 7, 2005, accepted June 15, 2005.Cholesterol, cholesteryl ester, and phospholipid circulate
n blood in macromolecular complexes called lipoproteins.
ichel Macheboeuf, in 1929, working at the Pasteur
nstitute, first described the plasma lipoproteins by using
mmonium sulfate fractionation of horse serum to isolate
lpha-lipoproteins, what today almost certainly would be
ecognized as high-density lipoprotein (HDL) (5). During
he Second World War, the need to improve transfusion
echnologies for the battlefield helped spark a great effort to
urify the constituents of blood plasma and serum. Two of
he leading laboratories involved in this effort were those of
dwin J. Cohn and J. L. Oncley (6,7). Later on, I had the
rivilege to meet Professor Oncley and learned a great deal
rom him about those early days, when they were isolating
uge amounts of plasma and serum with fractionation
rocedures that included precipitation under different acid
nd salt conditions, as well as electrophoresis. The original
lassification of the lipoproteins described an alpha- and a
eta-fraction of lipids and lipoproteins in blood, based on
heir electrophoretic migration with the alpha- and beta-
lobulins. The alpha-lipoproteins correspond with HDL,
nd the beta-lipoproteins comprised mainly LDL. A pre–
eta-fraction that migrated just in front of the beta-
lobulins has been characterized as including very low-
ensity lipoprotein (VLDL) and then, subsequently, was
hown to also contain a component called “sinking pre-beta”
hat was lipoprotein[a] (Lp[a]).
In 1951, Russ, Eder, and Barr (8,9), while at the New
ork Hospital, Cornell Medical Center, used the method-
logy of Cohn and Oncley to identify higher levels of
lpha-lipoprotein in young women compared with men.
hey presciently postulated that these higher concentrations
f the alpha-lipoprotein contributed to the lower cardiovas-
ular disease event rate seen in pre-menopausal women.
In 1949, the noted biophysicist John Gofman and his
olleagues at the University of California at Berkeley used
he newly developed ultracentrifuge to separate plasma
ipoproteins by flotation (10). Gofman observed that the
ipoprotein fraction that corresponds with LDL was asso-
iated with increased risk for cardiovascular disease and
howed that, in patients with familial hypercholesterolemia,
he cholesterol elevation was all in the LDL and
ntermediate-density lipoprotein fractions.
At the NIH, Donald Fredrickson took advantage of the
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36th Annual Louis F. Bishop Lecture October 4, 2005:1219–24reparative ultracentrifuge and paper electrophoresis, which
obert Lees and Fred Hatch had shown could give a better
eparation of lipoproteins if an albuminated buffer was used,
o characterize the lipoproteins further. In a series of
andmark articles in the New England Journal of Medicine
11), Fredrickson, Robert Levy, and Robert Lees described
classification system based on which groups of lipoproteins
ere elevated. Fredrickson phenotyping has proved to be a
opular schema for describing the dyslipidemias, although
redrickson’s categories made no attempt to distinguish
etween dyslipidemias with a primary or secondary etiology.
In those early days, two large observational trials played a
ey role in establishing the cardiac dangers of excess
holesterol levels. Ancel Keys’ Seven Countries Study (12),
uring the 1950s and 1960s, helped make the connection
etween dietary fat consumption, dyslipidemia, and coro-
ary risk. In those populations that consumed a higher
roportion of saturated fat as the total dietary caloric intake,
here were higher levels of cholesterol in the blood and a
igher incidence of congenital heart disease (CHD) mor-
ality.
Between 1948 and 1951, under the aegis of the National
eart Institute (the precursor to the National Heart, Lung,
nd Blood Institute [NHLBI]), the Framingham Heart
tudy began to collect longitudinal data on 1,980 men and
,421 women. In 1961, the Framingham investigators
ublished their six-year follow-up data (13). The study
howed that high blood pressure, smoking, and high cho-
esterol levels were major preventable factors in heart dis-
ase. The impact of the Framingham Heart Study on the
ecognition and management of atherosclerosis cannot be
verstated: it is primarily responsible for the concept of “risk
actors,” both modifiable and nonmodifiable, and has guided
he course of many decades of discussion of risk assessment.
The crux of the lipid hypothesis was that reducing
holesterol would reduce coronary events. The epidemiol-
gy had made a clear connection between cholesterol and
oronary risk, but, as we have seen today with antioxidants
nd with hormone replacement therapy in CHD preven-
ion, a relation established by epidemiologic or observational
tudies does not confirm a clinical benefit. An interventional
rial was needed.
S THE LIPID HYPOTHESIS CONFIRMED?
he Lipid Research Clinic Coronary Primary Prevention
rial (LRC-CPPT) (14), one of the most difficult trials in
hich I have participated, proved to be that trial. Each clinic
ite screened about 30,000 men in order to recruit 300 who
ualified for entry by having very high levels of LDL-C, no
vidence of coronary disease, and tolerance to the then-
vailable preparation of cholestyramine, which patients
ompared in texture and palatability to sand. Overall, the
rial recruited 3,806 middle-aged men with primary hyper-
holesterolemia. Although the drug was supposed to be
dministered as 24 g/day, patients could manage an average Sosage of around 12 g/day versus placebo. There was a 12%
eduction in LDL-C and 9% in total cholesterol, corre-
ponding to a reduction in CHD events of 19% after 7.4
ears of follow-up.
Despite some investigators who criticized the trial’s
esign and statistical analysis, LRC-CPPT confirmed for
any others that the fundamental premise of the lipid
ypothesis—that lipid modification was cardioprotective—
as sound and enhanced public awareness of the issue of
holesterol and heart disease. Inspired by this trial, Dan
teinberg chaired an NIH committee to put together a
ational Cholesterol Consensus (15). The NHLBI
aunched a program that turned into the National Choles-
erol Education Program. On September 1, 1987, lovastatin
ecame the first statin to be introduced into the market. A
ear later, the positive results of the primary-prevention
elsinki Heart Study of gemfibrozil were announced (16).
hus, all evidence seemed to be moving toward affirmation
f the lipid approach, although the lack of evidence showing
otal mortality benefit remained a key obstacle to wider
cceptance.
In 1989, the investigative reporter Thomas Moore
rote a cover story for the Atlantic Monthly magazine
ntitled, “The Cholesterol Myth,” with the tagline of
Lowering your cholesterol is next to impossible with diet,
ften dangerous with drugs, and it won’t make you live any
onger.” (17). Since that article’s publication, data have
massed that make it possible to challenge each of these
hree early criticisms. First, the lipid effects of diet are better
nderstood. Dansinger et al. (18) recently assessed the
ipid-modifying impact of four popular weight loss pro-
rams and also reported a one-year change in the LDL-C:
DL-cholesterol (HDL-C) ratio by approximately 10%, a
eduction that is consistent with the lipid changes expected
n the American Heart Association diet, which recom-
ends low consumption of saturated fats. Regardless of the
iet chosen, 12 months of weight loss was associated with
mprovements in the total cholesterol:HDL-C, C-reactive
rotein (CRP), and insulin levels. Poor patient adherence is
he greatest impediment to optimal implementation of
ietary therapy.
Second, a substantial body of evidence now illustrates the
afety of the most potent class of lipid-modifying drugs, the
tatins. Although one agent of this class, cerivastatin, was
emoved from the market in 2001 because of an enhanced
isk for fatal rhabdomyolysis, the rates of adverse events
ith the remaining are low and do not exceed the potential
enefits of therapy. An analysis of pharmacy benefit data
rom 11 managed-care health plans concluded that the
habdomyolysis rate was low and similar for atorvastatin,
ravastatin, and lovastatin (0.44 per 10,000 person-years of
reatment) (19).
Finally, three of the landmark statin trials were suffi-
iently powered to determine an effect on total mortality of
ctive treatment against placebo: a 30% reduction in the
candinavian Simvastatin Survival Study (4S); 22%, in the
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ase (LIPID) trial; and 13%, in the Heart Protection Study
20–22). Therefore, it may be said conclusively that lipid
odification can help improve survival in high-risk patients.
MERGING ROLE OF NON-LDL LIPID
ARKERS IN CHD RISK MANAGEMENT
lthough the clinical trials of statins have established that
argeting LDL-C yields coronary benefit, statin treatment
oes not completely abolish CHD risk, and many receiving
tatins nevertheless proceed to clinical coronary events.
hus, although LDL-C remains the primary “bad actor” in
therogenesis and is the first lipid target of therapy, research
as moved beyond LDL alone to include other lipid
ractions that may be contributing to the risk, such as
DL-C and triglycerides.
The Framingham Heart Study was one of the first to
bserve the inverse correlation between HDL-C and coro-
ary risk: the higher the HDL-C, the lower the risk for an
vent, to the extent that a 1-mg/dl increment in HDL-C
orresponded with 1% decrement in CHD risk (13).
There have been a number of trials with fibric acid
erivatives, the lipid-modifying drug class with primary
DL-C–raising and triglyceride-lowering effects (23).
one of these trials were powered to look at all-cause
ortality, but two of them have reported coronary risk
eductions with fibrate treatment compared with placebo:
he Helsinki Heart Study and the Veterans Affairs HDL-C
ntervention Trial (VA-HIT), a secondary-prevention study
ith gemfibrozil in post-myocardial infarction (MI) men.
n the VA-HIT, there was no reduction in LDL-C, but a
ignificant reduction in coronary events, attributed in part to
he effect of gemfibrozil on HDL-C (24). An interesting
nding from both studies was the post-hoc description of a
ertain subgroup of patients who appeared to benefit more
cutely from intervention than the overall cohort. In the
elsinki Heart study, high triglycerides, low HDL-C, and
igh LDL-C characterized the subgroup that experienced
he greatest relative risk reduction (25). This subgroup with
he “lipid triad” would be comparable to patients with the
etabolic syndrome, based on current criteria. In the
A-HIT, the patients who most benefited were those who
ither were diabetic or who had the metabolic syndrome
26). Therefore, fibrate treatment appears to be of particular
enefit in patients who have or are susceptible to diabetes or
ho have the metabolic syndrome.
Over a five-year period in the Air Force/Texas Coronary
therosclerosis Prevention Study (AFCAPS/TexCAPS),
reatment with lovastatin, 20 to 40 mg/day, reduced the risk
or a first acute major coronary event by 37% in low- to
oderate-risk men and women with below-average
DL-C (27). Logistic regression modeling to identify
hich lipids or apolipoproteins correlated best to event
eduction suggested that apolipoprotein A1, the major
rotein of HDL, and apolipoprotein B, the major protein of (therogenic lipoproteins, were the most consistently predic-
ive (28). These data have contributed to the ongoing debate
bout identifying the optimal lipid markers of CHD risk,
articularly with regard to apolipoprotein B, which many
tudies have proposed to be superior to LDL-C. Unfortu-
ately, the primacy of LDL in research and guidelines and
he entrenchment of its use in clinical practice have made it
ery difficult for new lipid markers to gain a foothold.
ROGRESS IN HDL THERAPIES
here may be several aspects to the cardioprotection asso-
iated with HDL, including reverse cholesterol transport
nd an antioxidant effect that prevents the modification of
he LDL particle, with consequent anti-inflammatory im-
lications. Three major pathways have been described (29)
hat could mediate cholesterol efflux from peripheral tissue
ith HDL: a passive diffusion pathway of cholesterol from
he vessel wall in the macrophage into a mature HDL
article; a pathway that involves scavenger receptor B-1
SR-B1); and a third pathway involving adenosine
riphosphate-binding cassette A1 (ABCA1) transporter,
hich is abnormal and deficient in the low HDL-C
yndrome Tangier disease, first described by Donald
redrickson and his colleagues.
Several novel therapies are in development that will try to
xploit the risk-reducing effect of HDL. Many of these
nvolve developing infusions of variants of apolipoprotein
I. A synthetic version of apolipoprotein AI Milano, a
enetic mutation first identified in a long-lived Italian
ommunity with low HDL-C levels, has suggested the
romise of this approach (30). In a multicenter, random-
zed, double-blind phase II trial of this agent (ETC-216),
7 subjects were randomized within two weeks of a coronary
vent to weekly intravenous infusion of ETC-216 (15 or 45
g/kg) or placebo. Patients received a maximum of five
oses, and intravascular ultrasonography was performed
efore the first dose and after the fifth. The primary end
oint, percent change in plaque volume at end of treatment
ersus baseline, was significantly reduced by the treatment.
he infusion yielded net regression of plaque burden, an
xciting but preliminary benefit that warrants additional
esearch. Another approach that is in the pipeline is the
evelopment of peptides that mimic the active part of
polipoprotein A1. Such a peptide would need to possess:
he ability to activate lecithin:cholesterol acyltransferase
LCAT), a key enzyme in reverse cholesterol transport;
holesterol-efflux capability; the ability to elevate HDL-C
n vivo; and anti-atherosclerotic activity. In 1974, Dr. Jere
egrest at the NIH and Drs. Richard Jackson, Joel Morris-
ett, and I at Baylor College of Medicine published an
mphipathic helical model to describe lipid-protein inter-
ctions in plasma lipoproteins (31). This model helped
nspire later research into the synthesis of consensus pep-
ides, one of which is currently under investigation
ESP24218, Esperion Therapeutics, personal communica-
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ased anti-atherosclerosis therapy. A number of other syn-
hetic analogues of apolipoprotein AI are also being studied.
Finally, inhibition of cholesteryl ester transfer protein
CETP), another key enzyme in HDL catabolism, is
aining acceptance as a novel treatment (32). The first
ETP inhibitor, torcetrapib, is being tested in a number of
arge trials. The evidence so far suggests that this drug will
aise HDL-C by 16% to 91%, depending on dosage, but
hether this will result in fewer coronary events remains to
e seen.
S LOWER BETTER?
he relation between cholesterol and coronary risk appears
o be linear, with no apparent threshold yet described below
hich cholesterol reduction would not yield further benefit.
n 2004, the Adult Treatment Panel of the National
holesterol Education Program (NCEP) revised its guide-
ines to permit an optional goal of 70 mg/dl for the
ighest-risk patients, which is lower than the 100-mg/dl
arget advocated in previous iterations (33). Although sev-
ral clinical trials helped shape this change, two studies were
f particular relevance. First was the Heart Protection
tudy, which showed consistent coronary benefit in high-
isk patients with moderate cholesterol elevations across the
ertiles of baseline LDL-C (22). On the basis of the Heart
rotection Study results, the U.S. Food and Drug Admin-
stration approved a revised indication for simvastatin that
llowed treatment of any high-risk patient, regardless of
DL-C. The other study, the Pravastatin or Atorvastatin
valuation And Infection Therapy (PROVE-IT) trial in
cute coronary syndrome patients assessed the effect of
ravastatin 40 mg/day versus atorvastatin 80 mg/day on
ecurrent events (34). There was a statistically significant
6% risk reduction in favor of atorvastatin, thus suggesting
hat more intensive lipid-lowering regimens have greater
linical benefits over moderate lipid-lowering regimens.
The results of the Treating to New Targets (TNT) trial
ave added further support to the claim of “lower is better”
35). A total of 10,003 patients in the TNT trial, ages 35 to
5 years, with LDL-C 130 to 250 mg/dl and triglycerides
600 mg/dl were treated with either atorvastatin 10 mg/day
r atorvastatin 80 mg/day. The LDL-C target for the
torvastatin 10-mg group was 100 mg/dl, and for the
torvastatin 80-mg group, 75 mg/dl. The primary end point
as time-to-occurrence of CHD death, non-fatal MI,
esuscitated coronary arrest, and fatal or non-fatal stroke.
ll-cause mortality was a secondary end point, but the study
as not powered to show a reduction in all-cause mortality.
HAT NEW AREAS HAVE BEEN OPENED BY
HE CONCEPT OF THE VULNERABLE PLAQUE?
or many years, atherosclerosis was thought to be an
nevitable accompaniment of aging. Russell Ross, among
thers, introduced the concept of atherosclerosis as a re- aponse to endothelial injury of the vessel wall (36). Mono-
ytes penetrate the intima, then differentiate into macro-
hages that scavenge minimally modified or oxidized LDL
articles and convert to foam cells. Apoptosis of these
ipid-laden cells account for deposition of a necrotic lipid
ore in the atheroma. Furthermore, activated macrophages
nd foam cells secrete cytokines growth factors and metal-
oproteinases, resulting in matrix degradation of the con-
ective tissue in the plaque. This vulnerable plaque is
usceptible to rupture, precipitating a cascade of thrombo-
enic events that result in vessel occlusion and a vascular
vent.
Inflammation is an integral participant in atherogenesis,
nd microbial infection by Chlamydia pneumoniae has been
ostulated to play a role in this process (37); however, the
enefits of anti-inflammatory agents, with the exception of
spirin, in the therapy of atherosclerosis remain speculative.
rials of anti-chlamydial agents have been generally nega-
ive, and cyclooxygenase (COX)-2 inhibitors, despite being
nti-inflammation drugs, may have deleterious cardiovascu-
ar effects (38–41). Statins may reduce the evidence of
nflammation, as measured by high-sensitivity CRP, but
hether or not this alone may protect against cardiovascular
isease remains to be established.
A post-hoc analysis of the AFCAPS/TexCAPS trial
xamined first coronary event rates in subgroups defined by
DL-C values above or below the median and CRP values
bove or below the median (42). The subgroup that had
DL-C above the median, regardless of whether CRP was
levated, had a trend toward benefit from lovastatin therapy,
nd the subgroup that had a CRP above the median had a
rend toward benefit regardless of whether the LDL-C was
bove or below the median. In the subgroup where both
DL-C and CRP were below the median (n  1,448),
owever, the event rate in the lovastatin group was no better
han that in the placebo group, suggesting that it may be
ossible to discriminate individuals in a population who may
ot benefit from statin therapy using both LDL-C and
RP.
Based on a post-hoc analysis of the PROVE-IT trial,
idker et al. (43) have put forth the argument that CRP has
oved from an inflammatory marker to a therapeutic target
n a “dual goal” approach to management. In the
ROVE-IT trial, patients achieving on-treatment LDL-C
70 mg/dl had a greater number of events than those 70
g/dl. At the same time, those who had on-treatment CRP
2 mg/l experienced a greater number of events than those
2 mg/l. There was no correlation (r  0.18) between
chieved LDL-C and CRP. Choice of statin appeared to be
ess important than achieving the goals of LDL-C 70
g/dl and CRP 2 mg/l, although atorvastatin resulted in
ore patients achieving both goals. Of the entire cohort in
he PROVE-IT trial, 27% achieved both LDL-C 70
g/dl and CRP 2 mg/l. This subgroup, after adjustment
or age, gender, smoking, diabetes, hypertension, obesity,
nd HDL-C, had a 29% lower risk for recurrent MI or
c
n
a
c
b
i
d
d
s
a
m
(
(
a
s
m
c
a
C
A
i
i
p
o
a
l
F
a
i
c
w
t
i
i
a
i
h
s
l
o
A
T
p
C
h
R
J
4
E
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
1223JACC Vol. 46, No. 7, 2005 Gotto, Jr.
October 4, 2005:1219–24 36th Annual Louis F. Bishop Lectureardiovascular death (p  0.04) (44). Further research is
eeded to answer the question of whether changes in CRP,
nd by extension in inflammation, account for any of the
oronary benefit observed with the statins.
Even more intriguing are data that suggest hypothetical
enefits of statins in other disease states with features of
nflammation, such as a number of immune-mediated
isorders like multiple sclerosis, rheumatoid arthritis, type 1
iabetes, and graft rejection in organ transplantation (45). A
mall study reported fewer gadolinium-enhancing lesions
nd fewer new lesions in a group of patients with relapsing
ultiple sclerosis treated with 80 mg/day of simvastatin
46). The Trial of Atorvastatin in Rheumatoid Arthritis
TARA) reported modest improvements in rheumatoid
rthritis disease activity scores and swollen joint counts in a
mall number of patients who received atorvastatin 40
g/day, versus placebo (47). Furthermore, a potential anti-
ancer effect has been reported in some observational
nalyses that warrant additional consideration (48).
ONCLUSIONS
therosclerosis was once thought to be an irreversible,
nevitable consequence of aging. The recognition of dyslip-
demia as a major modifiable risk factor introduced the
ossibilities of both treatment and prevention. The advent
f the statins ushered in an era of landmark trials that
ffirmed the basic tenets of the lipid hypothesis and estab-
ished a definitive mortality benefit with cholesterol control.
urthermore, the statin trials helped extend the view of
therosclerosis management beyond the coronary arteries to
nclude both other cardiovascular manifestations, such as
arotid disease and peripheral arterial disease, and diabetes,
hose associated cardiovascular risk justifies aggressive in-
ervention.
The improved understanding of the role of lipid disorders
n cardiovascular disease over the decades has generated new
nsights into the pathology of atherosclerosis, opened new
reas of investigation, and created new opportunities for
ntervention. Although the successes of the last 50 years
ave been extraordinary, much of the landscape of athero-
clerosis remains uncharted and poorly understood. Tack-
ing the challenges of that exploration will shape the future
f the field, with the best yet to come.
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